Alamar Biosciences showcased NULISA data in 46 presentations at the CTAD conference, advancing Alzheimer's disease research and diagnostics.
Quiver AI Summary
Alamar Biosciences, Inc. announced that its NULISA™ precision proteomic platform will be featured in 46 presentations at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston from November 16 to 19, 2026. These presentations, contributing to critical advancements in Alzheimer’s research, highlight the application of NULISA for patient risk identification, clinical trial enrollment, and treatment response measurement. Since launching in January 2024, NULISA has been referenced in numerous studies aimed at improving the early detection and treatment of Alzheimer's disease. The conference presentations showcase data from various clinical trials and research efforts, emphasizing the significance of blood biomarkers and the platform's capability to analyze multiple proteins at once, facilitating better understanding of disease biology and enhancing diagnostic accuracy. Alamar’s CEO, Yuling Luo, expressed gratitude to collaborators for their contributions, which will ultimately benefit patients.
Potential Positives
- Alamar Biosciences’ NULISA™ platform is highlighted in 46 presentations at the prestigious Clinical Trials on Alzheimer's Disease (CTAD) conference, showcasing its significant role in advancing Alzheimer's research.
- The technology has been utilized in multiple stages of Alzheimer's research, underlining its versatility and importance in areas such as patient risk identification and monitoring treatment responses.
- Since its launch in January 2024, NULISA has been cited in hundreds of research publications, indicating strong acceptance and reliance on the technology within the scientific community.
- The press release emphasizes advancements in blood-based biomarkers for diagnosing Alzheimer’s, positioning Alamar at the forefront of this critical shift in research and clinical trials.
Potential Negatives
- Forward-looking statements in the release caution that actual results may differ materially from the company's expectations, indicating potential uncertainty regarding the performance and acceptance of the NULISA platform.
- The press release highlights intense competition in the proteomics market, suggesting that Alamar may face challenges in maintaining its market position.
- Concerns over dependence on government funding for research and the potential for reduced spending by research and academic institutions could impact future growth and financial stability.
FAQ
What is the NULISA™ platform by Alamar Biosciences?
The NULISA™ platform is a precision proteomic technology designed for ultra-sensitive protein biomarker detection in blood.
How many presentations will feature NULISA data at CTAD 2026?
There will be a total of 46 presentations that feature data generated with the NULISA platform at CTAD 2026.
Who is presenting at the CTAD conference?
The presentations come from researchers at various academic centers, clinical research institutes, and biopharmaceutical companies across the U.S., Europe, and Asia.
What advancements in Alzheimer’s research does NULISA support?
NULISA aids in identifying at-risk patients, enrolling participants in trials, and measuring treatment responses in Alzheimer's research.
When was NULISA technology commercially launched?
NULISA technology was officially launched in January 2024 and has been cited in numerous research publications since then.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALMR Insider Trading Activity
$ALMR insiders have traded $ALMR stock on the open market 128 times in the past 6 months. Of those trades, 0 have been purchases and 128 have been sales.
Here’s a breakdown of recent trading of $ALMR stock by insiders over the last 6 months:
- CORPORATE GP VI, LTD. QIMING has made 0 purchases and 128 sales selling 1,599,066 shares for an estimated $47,502,975.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALMR Hedge Fund Activity
We have seen 87 institutional investors add shares of $ALMR stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SAMSARA BIOCAPITAL, LLC added 2,480,310 shares (+inf%) to their portfolio in Q2 2026, for an estimated $67,191,597
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,202,597 shares (+inf%) to their portfolio in Q2 2026, for an estimated $59,668,352
- BRAIDWELL LP added 1,083,983 shares (+inf%) to their portfolio in Q2 2026, for an estimated $29,365,099
- ALLIANCEBERNSTEIN L.P. added 1,003,077 shares (+inf%) to their portfolio in Q2 2026, for an estimated $27,173,355
- HHLR ADVISORS, LTD. added 956,462 shares (+inf%) to their portfolio in Q2 2026, for an estimated $25,910,555
- MILLENNIUM MANAGEMENT LLC added 865,764 shares (+inf%) to their portfolio in Q2 2026, for an estimated $23,453,546
- PURA VIDA INVESTMENTS, LLC added 755,909 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,477,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALMR Analyst Ratings
Wall Street analysts have issued reports on $ALMR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 11/04/2026
- Stifel issued a "Buy" rating on 08/11/2026
- JP Morgan issued a "Overweight" rating on 08/11/2026
To track analyst ratings and price targets for $ALMR, check out Quiver Quantitative's $ALMR forecast page.
$ALMR Price Targets
Multiple analysts have issued price targets for $ALMR recently. We have seen 3 analysts offer price targets for $ALMR in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Dan Brennan from TD Cowen set a target price of $36.0 on 11/04/2026
- Daniel Arias from Stifel set a target price of $32.0 on 08/11/2026
- Casey Woodring from JP Morgan set a target price of $35.0 on 08/11/2026
Full Release
Fremont, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences , Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data generated with its NULISA™ precision proteomic platform will be featured in 46 presentations, including 10 oral presentations, at the Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16 to 19, 2026, in Boston.
The presentations come from researchers at academic centers, clinical research institutes and biopharmaceutical companies in the United States, Europe and Asia. Together they show NULISA being used at each stage of Alzheimer's research, from identifying who is at risk and enrolling the right patients in clinical trials to measuring how patients respond to treatment.
Since its commercial launch in January 2024, Alamar’s NULISA technology has been cited in hundreds of research publications worldwide, including studies advancing the early detection, diagnosis, monitoring and treatment of Alzheimer’s disease.
"Given the advances in blood-based biomarkers for diagnosing Alzheimer's, research is shifting toward treatment, and that shift depends on measuring many proteins in blood with enough sensitivity to see small changes over time," said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. "This year's CTAD presentations show researchers using NULISA to screen patients, enrich clinical trials and follow therapeutic response, often in the same study. The breadth of this work reinforces NULISA's position as the leading multiplex platform in Alzheimer’s research. We are grateful to our collaborators for this work and for what it means for the patients who will benefit from it."
“Blood biomarkers have transformed how we diagnose Alzheimer’s disease and conduct clinical trials. With the development of an ultrasensitive singleplex assay for plasma eMTBR-tau, we are moving closer to characterizing the two fundamental pathological hallmarks of Alzheimer’s disease—amyloid plaques and tau tangles—through a simple blood sample,” said Nicholas Ashton, PhD, senior director of the Fluid Biomarker Laboratory at Banner Health.
“This represents an important step toward more precise disease staging and monitoring. Beyond these core pathologies, the ability to measure hundreds of proteins simultaneously using sensitive multiplex platforms such as NULISA offers an exciting opportunity to deepen our understanding of disease biology, identify additional pathological processes, and ultimately improve diagnostic and prognostic accuracy. Together, these approaches could transform how we characterize Alzheimer’s disease and guide future clinical trials and treatment strategies.”
Across the 46 presentations, researchers applied NULISA to blood and cerebrospinal fluid samples from clinical trials, real-world treatment cohorts, autopsy-confirmed cases and people at risk for Alzheimer's disease. The data fall into three areas:
- Therapeutic response: Fluid biomarker results from Johnson & Johnson's Phase 2 Autonomy trial of an anti-tau therapy, plasma data from the Phase 3 APOLLOE4 trial of valiltramiprosate, longitudinal and real-world multicenter studies of patients treated with lecanemab, new findings on plasma biomarkers of ARIA and preclinical pharmacodynamic data for a next-generation biparatopic tau antibody.
- Better blood tests: Brain-derived p-tau217 showed the strongest association with amyloid and tau accumulation and cognitive progression among 328 plasma proteins in the A4 and LEARN studies. A brain-derived p-tau217 measure tracked disease pathology and progression, and combining p-tau217 with proteomic signatures enabled graded risk stratification. Additional studies address false positive p-tau217 results linked to chronic kidney diseases, validate capillary blood sampling and show a NULISA panel that improves amyloid positivity detection for trial enrichment.
- Expanding the biology: Ultrasensitive measurement of plasma eMTBR-tau, including as a biomarker of tau pathology in chronic traumatic encephalopathy, along with new work on TDP-43 loss of function, APOE ε4 screening and amyloid chronicity in autosomal dominant Alzheimer's disease.
Oral presentations
All oral presentations will take place at the Boston Marriott Copley Place, in the Ballroom, 4th floor.
| Date | Time | Presentation Number and Title | Presenter |
| Mon, Nov 16 | 4:20 p.m. | OC3: Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification | Nicholas Ashton, Banner Sun Health Research Institute |
| Tue, Nov 17 | 8:30 to 9:10 a.m. (Symposium 2) | Symposium 2, Presentation 2: CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial | Gallen Triana-Baltzer, Johnson & Johnson |
| Tue, Nov 17 | 8:30 to 9:10 a.m. (Symposium 2) | Symposium 2, Presentation 3: Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial | Gil D. Rabinovici, UCSF |
| Tue, Nov 17 | 4:00 p.m. | OC18: Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study | Adrian Noriega De La Colina, Broad Institute of MIT and Harvard / MIT |
| Wed, Nov 18 | 8:30 a.m. | OC19: Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies | Robert Rissman, University of Southern California |
| Wed, Nov 18 | 2:40 p.m. | OC33: Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score (Units) | Wagner S. Brum, ZRO Imaging, Santiago de Compostela |
| Wed, Nov 18 | 4:45 p.m. | OC39: Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression | Menghan Liu, Washington University School of Medicine |
| Thu, Nov 19 | 9:25 a.m. | OC41: CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression | Thomas K. Karikari, University of Pittsburgh |
| Thu, Nov 19 | 1:05 p.m. | OC48: Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study | Rui Mu, Washington University School of Medicine |
| Thu, Nov 19 | 1:50 p.m. | OC51: Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology | Annalise E. Miner, Boston University CTE Center and ADRC |
See here for a full list of posters and presentations featuring NULISA data at CTAD 2026.
About Alamar Biosciences
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com .
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding, the ability of the NULISA platform to generate proteomic insights and potential to help researchers gain an understanding of how patients will progress or respond to therapies . Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the execution of the collaboration with GSK, intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.